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Majidat A. Muhammad,a Russell R. Bakken,a Laura I. Prugar,a Gene G. Olinger,a Jennifer L. Groebner,a* John S. Lee,a*
William D. Pratt,a Max Custer,b* Kurt I. Kamrud,b* Jonathan F. Smith,b* Mary Kate Hart,a* John M. Dyea
U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland, USAa; AlphaVax, Inc., Research Triangle Park, North Carolina, USAb
There are no vaccines or therapeutics currently approved for the prevention or treatment of ebolavirus infection. Previously, a
replicon vaccine based on Venezuelan equine encephalitis virus (VEEV) demonstrated protective efficacy against Marburg virus
in nonhuman primates. Here, we report the protective efficacy of Sudan virus (SUDV)- and Ebola virus (EBOV)-specific VEEV
replicon particle (VRP) vaccines in nonhuman primates. VRP vaccines were developed to express the glycoprotein (GP) of either
SUDV or EBOV. A single intramuscular vaccination of cynomolgus macaques with VRP expressing SUDVGP provided com-
plete protection against intramuscular challenge with SUDV. Vaccination against SUDV and subsequent survival of SUDV chal-
lenge did not fully protect cynomolgus macaques against intramuscular EBOV back-challenge. However, a single simultaneous
intramuscular vaccination with VRP expressing SUDVGP combined with VRP expressing EBOVGP did provide complete pro-
tection against intramuscular challenge with either SUDV or EBOV in cynomolgus macaques. Finally, intramuscular vaccina-
tion with VRP expressing SUDVGP completely protected cynomolgus macaques when challenged with aerosolized SUDV, al-
though complete protection against aerosol challenge required two vaccinations with this vaccine.
Ebolaviruses and marburgviruses, members of the family Filo-viridae, cause sporadic viral hemorrhagic fever outbreaks that
primarily affect areas of equatorial Africa (1). Two marburgvi-
ruses, Marburg virus (MARV) and Ravn virus (RAVV), and five
ebolaviruses, Bundibugyo virus (BDBV), Reston virus (RESTV),
Sudan virus (SUDV), Tai Forest virus (TAFV), and Ebola virus
(EBOV), are currently recognized. (2). The filovirus genome con-
sists of a nonsegmented, single-strand negative-sense RNAmole-
cule 19 kb in length encoding the following genes: 3=-NP-VP35-
VP40-GP-VP30-VP24-L-5= (3). These enveloped viruses have
filamentous morphology with a uniform diameter of 80 nm and
highly variable lengths. Primates represent accidental hosts for
filoviruses with devastating consequences since fatality rates asso-
ciated with infection can be as high as 90% in humans (4). African
fruit bats are the presumptive natural reservoir host for filoviruses
(5–8), although the mechanism by which these viruses make the
jump from their reservoir host into human and nonhuman pri-
mate (NHP) populations is not well understood (9). Once intro-
duced into primate populations, filovirus transmission occurs pri-
marily through contact with bodily fluids, although recent
evidence suggests that other modes of transmission may exist,
including aerosol (10, 11). Experimental evidence has clearly
demonstrated the ease with which nonhuman primates can be
infected with filoviruses by the aerosol route under controlled
laboratory conditions (12, 13). Aerosol transmission is of partic-
ular importance for biodefense since this represents the most
likely means of dissemination (14). Accordingly, filovirus vaccine
development efforts will likely need to focus on providing protec-
tion against aerosol exposure, in addition to other routes of infec-
tion.
EBOV and SUDV are responsible for the largest number of
human ebolavirus infection cases to date and represent the chief
ebolaviruses for which vaccines are currently being developed.
Several efficacious ebolavirus vaccines developed over the last de-
cade have demonstrated that a single ebolavirus antigen, glyco-
protein (GP), is sufficient to provide protection against homolo-
gous challenge (15). GP, the sole surface viral protein, is
responsible for mediating cell attachment and viral entry and is
the primary target of humoral immunity (16, 17). Due to the
limited amino acid homology of GP across ebolaviruses (55 to
60% homologous) (3), vaccines employing GP from a single
ebolavirus have yet to demonstrate complete cross-protection
against heterologous ebolavirus challenge. However, ebolavirus
vaccines based on vesicular stomatitis virus (VSV) and adenovirus
vectors expressing homologous ebolavirus genes have shown pro-
tective efficacy in NHPs against multiple ebolaviruses after intra-
muscular (i.m.) challenge (18, 19). Prior to the current studies, the
VSV- and adenovirus-based vaccine platforms are the only ebola-
virus vaccine candidates reported to protect NHPs from aerosol
exposure to ebolavirus, and the adenovirus-based vaccine is the
only vaccine that has demonstrated protection against aerosolized
SUDV (19, 20). At present, there are no filovirus vaccines ap-
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proved for human use, although several candidate vaccines are
being readied for clinical trials (21).
The Venezuelan equine encephalitis virus (VEEV) replicon
particle vaccine platform, first developed by Pushko et al. (22), is a
promising vaccine platform, due in part to its tropism for den-
dritic cells and its ability to produce high levels of target antigen
(22, 23). The platform relies on a modified alphavirus genome in
which the structural genes downstream of a subgenomic pro-
moter are replaced by a heterologous gene of interest (24). Repli-
con RNAs, containing all genes for the replicase complex, are as-
sembled into replicon particles by coexpressing alphavirus
structural proteins in trans (25, 26). Upon delivery of the VEEV
replicon particle (VRP), the replicase complex drives the expres-
sion of the heterologous gene of interest from the subgenomic
RNA. Replicon RNA delivered to cells by the VRP contains no
structural genes since the structural genes supplied in trans during
production lack packaging signals, resulting in a single round of
replication (27). The VRP platform has been utilized to develop
vaccines for numerous tumor, viral, and bacterial antigens (27).
The expression of filovirus proteins by VRPs provides protection
against filoviruses in rodent models (28, 29), and the VRP vaccine
was the first vaccine platform to demonstrate protection of NHPs
against filovirus challenge (30). In these studies, cynomolgus ma-
caques were completely protected against subcutaneous (s.c.)
challenge with MARV when vaccinated s.c. with VRP expressing
MARV GP alone or MARV GP in combination with MARV NP
but only partially protected (two of three animals) when vacci-
nated with VRP expressing MARV NP alone. However, an analo-
gous study designed to protect macaques against i.m. challenge
with EBOVusing VRP expressing EBOVGP orNP proved unsuc-
cessful (31). Subsequent studies were carried out using higher
doses of VRP vaccine, made possible by improvements in VRP
manufacturing and downstream processing (32–35). Here, we re-
port that VRPs expressing EBOV GP or SUDV GP can elicit im-
mune responses that are sufficient to protect NHPs against, not
only i.m. challenge, but also against aerosol exposure to homolo-
gous virus.
MATERIALS AND METHODS
Ethics statement.Animal research was conducted in compliance with the
Animal Welfare Act and other federal statutes and regulations relating to
animals and experiments involving animals and adhered to the principles
stated in the Guide for the Care and Use of Laboratory Animals (National
Research Council, 2011). The facility is fully accredited by the Association
for the Assessment and Accreditation of Laboratory Animal Care Inter-
national. All challenge studies were conducted under maximum contain-
ment in an animal biosafety level 4 (BSL-4) facility at U.S. Army Medical
Research Institute of Infectious Diseases (USAMRIID) and were ap-
proved by theUSAMRIID Institutional Animal Care andUse Committee.
Due to ethical considerations stemming from the near universal lethality
of infection and as is standard practice for NHP studies with filoviruses,
historical controls were sometimes used to limit the number of animals
required. In these studies, all control animals succumbed to filovirus chal-
lenge within the normal time to death.
Cells and viruses. Vero E6 cells utilized for plaque assays were main-
tained in Eagle minimal essential medium (EMEM) supplemented with
5% heat-inactivated fetal bovine serum (FBS) and gentamicin (50g/ml)
at 37°C, 5%CO2, and 80% humidity. BHK-21 cells utilized for VRP anal-
ysis were maintained in EMEM supplemented with 10% heat-inactivated
FBS, 2mML-glutamine, and gentamicin (50g/ml) at 37°C, 5%CO2, and
80% humidity. The Boniface isolate of SUDV was used for all SUDV
challenge experiments and the Kikwit 95 isolate of EBOV was used for all
EBOV challenge experiments.
Vaccination and challenge. Naive cynomolgus macaques, 2.6 to 6.7
kg, were vaccinated intramuscularly (i.m.) with 1010 focus-forming units
(FFU) of indicated VRP vaccine diluted in 0.5 ml of phosphate-buffered
saline (PBS). For simultaneous vaccinations with VRP-SUDV GP and
VRP-EBOV GP, vaccines were delivered in the quadriceps muscle of op-
posing legs. NHPs receivingmultiple doses of VRP-SUDVGP received an
additional vaccination, as described above, 28 days after the initial dose.
For i.m. challenge experiments, NHPs were challenged by i.m. injection
with a target dose of 1,000 PFU of indicated virus diluted in 0.5ml of PBS.
Titration of challenge inocula determined that NHPs received between
887 and 1,050 PFU of SUDV and between 943 and 1,012 PFU of EBOV.
For aerosol challenge experiments, NHPs were challenged with a target
dose of 100 PFU The method used for aerosol exposures has been previ-
ously described (36). In brief, the NHPs were anesthetized by i.m. injec-
tion with tiletamine/zolazepam (6 mg/kg) or ketamine-acepromazine (9
mg of ketamine and 0.1 mg of acepromazine/kg). Whole-body plethyso-
mography was performed under the plane of anesthesia (Buxco Research
Systems, Wilmington, NC) for calculation of the respiratory minute vol-
ume. Animals were then exposed to SUDV in a head-only aerosol cham-
ber within a class III biological safety cabinet for a time-calculated aerosol
exposure. Aerosols were generated using a 3-jet Collison nebulizer (BGI,
Inc., Waltham, MA) controlled by the automated exposure control sys-
tem. The generated aerosol was sampled with an all-glass impinger (AGI)
containing 10 ml of collection medium (EMEM/nonessential amino ac-
ids, 10% FBS, 0.1% gentamicin, and 0.001% antifoam A). Immediately
after the exposure, AGI samples were analyzed by plaque assay. The in-
haled dose was calculated for each NHP by using the following formula:
dose Vm t Ce, where Vm is the respiratory minute volume, t is the
duration of the exposure, and Ce is the aerosol concentration (37). The
exposure timewas calculated based on theminute volume of eachNHP so
that the same inhaled dose could be delivered to each dose group. Titra-
tion of challenge inocula for aerosol exposures determined that NHPs
received between 16 and 132 PFU of SUDV. Challenged animals were
monitored closely for at least 28 days after challenge.
Hematology and blood biochemistry. Phlebotomy was performed
while the animals were anesthetized, and blood was collected from the
femoral vein using a venous blood collection system (Becton Dickinson,
Franklin, NJ). Viremia was determined using traditional plaque assay
(38). Hematological values for blood samples collected in tubes contain-
ing EDTA were determined using a hematologic analyzer (Coulter Elec-
tronics, Hialeah, FL). Serum biochemistry panels were measured using a
Piccolo point-of-care blood analyzer (Abaxis, Sunnyvale, CA).
Postmortem examination. For all of the animal studies described
above, the body of each NHP that succumbed or was euthanized due to
the severity of clinical disease was submitted for a gross necropsy in BSL-4
containment. In addition, the three animals vaccinated twice with VRP-
SUDV GP (experimental animals 16, 17, and 18), which survived a chal-
lenge with aerosolized SUDV, were euthanized at the end of the study and
submitted for necropsy. Euthanasia and necropsy were also performed on
four animals that survived an initial viral challenge with SUDV and back-
challenge with EBOV: two NHPs (experimental animals 3 and 4) which
had been vaccinatedwith just VRP-SUDVGPand twoNHPs (experimen-
tal animals 11 and 12) which received vaccination with both VRP-SUDV
GP and VRP-EBOV GP.
For experiments in which the route of viral challenge was i.m., partial
necropsies were conducted on all control animals and four of the vacci-
nated animals. Complete necropsies were performed on five of the vacci-
nated NHPs from the i.m. challenge studies and on all animals that had
been exposed by an aerosol route of challenge. The partial necropsies were
done to confirm the presence (or absence) of lesions in organs typically
affected by ebolaviruses following a lethal i.m. challenge; samples of the
following organs were collected from each animal and fixed in 10% buff-
ered formalin for histology: liver, spleen, adrenal gland, kidney, gonad,
VRP Vaccine Protects NHPs from Ebolavirus Challenge
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and axillary, inguinal, andmesenteric lymphnodes. The sameorganswere
sampled for histology during complete necropsies and, in addition, sam-
ples of brain, pituitary gland, eyes, heart, upper and lower respiratory
tract, tonsil, mandibular lymph node, mediastinal lymph node, urinary
bladder, bone marrow, tongue, esophagus, pancreas, and all levels of the
gastrointestinal tract were collected.
The set of formalin-fixed tissue samples from each NHP was held in
BSL-4 containment for a minimum of 21 days and then transferred to the
USAMRIID histopathology laboratory. All tissue samples were trimmed,
routinely processed, and embedded in paraffin. Sections of the paraffin-
embedded tissues were cut (5mthick) for histology. The histology slides
were deparaffinized, stained using hematoxylin and eosin, and placed
under coverslips.
IHC. Immunohistochemistry (IHC) to detect the presence of viral
antigen in tissue samples was performed on all NHPs that had been ex-
posed to aerosolized virus. A replicate set of unstained sections from the
paraffin-embedded tissues used for histology was made and attached to
glass slides. Sections were deparaffinized and exposed for 60 min to a
rabbit polyclonal antibody produced against EBOV (cross-reactive with
SUDV) or 30 min to an equal mix of two mouse monoclonal antibodies
against MARV. Peroxidase-labeled secondary antibody and chromogen
was then applied to the fixed tissues. Slides were counterstained with
hematoxylin and then covered with a glass coverslip.
ELISA. Filovirus-specific serum IgG titers were determined by enzyme
linked immunosorbent assay (ELISA) using recombinant SUDV or re-
combinant EBOV GP and as previously described (39). Briefly, polyvinyl
chloride ELISA plates (Dynatech Laboratories, Chantilly, VA) were incu-
bated with respective recombinant GP antigens, diluted in PBS (2 g/ml,
50l/well), overnight at 4°C. Plates were blocked with 5%milk protein in
PBS–0.02% Tween 20 at room temperature. Serum samples were diluted
in blocking buffer supplemented with 1% goat serum and serial 0.5-log
dilutions were performed. Antigen-coated ELISA plates were incubated
with diluted serum samples for 2 h at room temperature and then washed
with wash buffer (PBS, 0.02% Tween 20). Plates were incubated with
horseradish peroxidase-conjugated goat anti-NHP IgG (Rockland, Gil-
bertsville, PA) diluted in blocking buffer for 1 h at room temperature. The
plates were washed as described above prior to the addition of ABTS [2,
2=-azino-di(3-ethylbenzthiazoline-6-sulfonate)] substrate (Kirkegaard
and Perry Laboratories, Inc., Gaithersburg,MD). Absorbance values were
read at 405 nm using a Spectramax plate reader (Molecular Devices, LLC,
Sunnyvale, CA). To determine the cutoff values for each dilution, prevac-
cination serum samples from each individual NHP were run in parallel
with postvaccination and postchallenge samples. Cutoff values for each
dilution were calculated using absorbance values of prevaccination serum
for that dilution and the following formula; average prevaccination serum
absorbance 3 the standard deviation. Endpoint titers for each serum
sample are expressed as the last dilution to exceed the cutoff value for a
given dilution.
Immunofluorescence microscopy. BHK cells grown on coverslips
were infected with VRP expressing influenza virus hemagglutinin, EBOV
GP, or SUDV GP at a multiplicity of infection of 10, followed by incuba-
tion at 37°C, 5% CO2, and 80% humidity for 24 h. The cells were then
washed three times with PBS and fixed using ice-coldmethanol for 5min.
The methanol was removed and the cells were allowed to air dry before
incubating them with blocking buffer (5% milk protein in PBS–0.02%
Tween 20) overnight at 4°C. The fixed cells were then incubated with
EBOV GP-specific human monoclonal antibody KZ52 (kindly provided
by Dennis Burton, The Scripps Research Institute, La Jolla, CA) or SUDV
GP specific mouse monoclonal antibodies 3C10. Cells were incubated
with secondary antibody goat anti-human IgG-488 or goat anti-mouse
IgG-488 (Molecular Probes, Eugene, OR) prior to mounting the cover-
slips on glass slides using ProlongGold antifade reagent withDAPI (4=,6=-
diamidino-2-phenylindole; Molecular Probes). Images were capture on a
Zeiss Axio Observer.Z1 microscope using Zen 2011 image acquisition
software (Carl Zeiss, Oberkochen, Germany).
Real-time RT-PCR assay. Real-time reverse transcription PCR (RT-
PCR) assayswere completed as previously reported (40). Briefly, RNAwas
purified from whole blood that was collected 7 days postchallenge using
TRIzol-LS reagent (Invitrogen, Inc., Carlsbad, CA). Real-time RT-PCR
was accomplished using a SuperScript One-Step RT-PCR kit (Invitrogen)
with a final concentration of 3 mM MgSO4 and one of the following
primer-probe sets: forMARV, F6121 (1M), F6121-1 (1.5M),R6184 (1
M), and p6144 (0.2M); for EBOV, F2000 (1M), R2079 (1M), and
p2058A (0.1 M); and for SUDV, F583 (0.8 M), R659 (0.8 M), and
p608SB (0.1 M) (40). Real-time RT-PCR amplification was performed
as follows: 50°C for 15 min (1 cycle), 95°C for 5 min (1 cycle), 95°C for 1
s and 60°C for 20 s (45 cycles), and 40°C for 30 s (1 cycle), using a Light-
Cycler 2.0 (Roche Applied Sciences, Penzberg, Germany) thermal cycler.
Fluorescence was measured at the end of each 60°C step.
Statistical analysis. Prism software (GraphPad, Inc., San Diego, CA)
was used to graph and to conduct statistical comparisons of all data as
described in the text. The Fisher exact test (two-tailed) was used to deter-
mine statistical differences in survival between the groups that received
the ebolavirus VRP vaccines and between the corresponding negative
control groups.
RESULTS
SUDV GP expressing VRP vaccine elicits protective immunity
against i.m. challenge with SUDV. VRPs expressing SUDV
(Boniface) GP or EBOV (Kikwit) GP were generated using pro-
duction methods previously described (28, 32–35). SUDV GP
and EBOV GP expression was evaluated by immunofluores-
cence in vitro prior to vaccination (Fig. 1). To determine the
protective efficacy of filovirus VRP vaccines in NHPs against
i.m. ebolavirus exposure, we vaccinated six experimental cyn-
omolgus macaques i.m. with a single dose of 1010 FFU of VRP-
SUDV GP and two control cynomolgus macaques i.m. with
1010 FFU of VRP expressing an irrelevant antigen (smallpox
A33R). No adverse events were reported in the days following
vaccination, and no local reactions were observed in any of the
animals, either in the present study or subsequent studies. Se-
rum samples were collected following vaccination and evalu-
ated by ELISA to determine SUDV GP-specific antibody titers.
FIG 1 VRP expression of Ebola virus and Sudan virus GP. BHK cells were
infected with VRP expressing influenza virus hemagglutinin (A and B), EBOV
GP (C), or SUDVGP (D). GP expressionwas detected using EBOVGP specific
monoclonal antibody KZ52 (A and C) or SUDV GP specific monoclonal an-
tibody 3C10 (B and D), and nuclei were stained with DAPI.
Herbert et al.
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The VRP-SUDV GP vaccine induced elevated (4.5 to 5.75 logs)
SUDV GP-specific serum IgG titers in all NHPs 14 days after
vaccination, and these titers remained high in five of the six
NHPs out to 28 days postvaccination (Fig. 2A). All NHPs were
challenged 28 days postvaccination with a target dose of 1,000
PFU of SUDV delivered by i.m. injection. Control animals suc-
cumbed to infection on days 8 and 9 postinfection with classic
clinical signs of ebolavirus disease, including elevated serum
enzymes, rash, thrombocytopenia, and viremia. Postmortem
examination confirmed that these NHPs died due to ebolavirus
infection, and there were no other confounding diseases noted.
In contrast, all VRP-SUDV GP vaccinated animals survived
i.m. challenge with few clinical signs of disease and no detect-
able viremia (Fig. 2C, Table 1).
Vaccination against SUDV and subsequent survival of
SUDV challenge does not confer protection against EBOV chal-
lenge.Despite eliciting high levels of cross-reactive EBOVGP spe-
cific serum IgG antibodies (Fig. 2B), VRP-SUDV GP vaccination
and survival of SUDV challenge provided only partial protection
against heterologous EBOV challenge. Only two of six SUDV sur-
vivors were protected against EBOV back-challenge when ex-
posed to a target dose of 1,000 PFU of EBOV i.m. 30 or 35 days
after SUDV challenge (Fig. 2D, Table 1). Both naiveNHP controls
in this experiment and two SUDV survivors succumbed to EBOV
challenge on days 7 and 8, within the expected time-to-death win-
dow for naive cynomolgus macaques given a lethal i.m. dose of
EBOV (18, 19, 31). Two other SUDV survivors succumbed to
EBOV challenge on days 14 and 18, several days outside of the
FIG 2 VRP-SUDVGPprotects cynomolgusmacaques from SUDV i.m. challenge. NHPswere vaccinatedwith VRP expressing irrelevant antigen (n 2) or VRP
expressing SUDVGP (n 6). SUDVGP (A) or EBOVGP (B) specific serumantibody end titers were determined by ELISA at the indicated times postvaccination
or challenge. Dotted line indicates assay limit of detection. Black and red arrows indicate time of SUDV challenge and EBOV back-challenge, respectively. (C)
NHPswere challenged by i.m. injection of 1,000 PFUof SUDV28 days postvaccination. (D) SurvivingNHPswere then back-challenged by i.m. injection of 1,000
PFU of EBOV 30 or 35 days post-SUDV challenge. ***, P 0.001 (as determined by the Fisher exact test).
VRP Vaccine Protects NHPs from Ebolavirus Challenge
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expected time-to-death window. Nonetheless, all six NHPs that
died after EBOV challenge, including the two controls, presented
clinical signs typical of EBOV infection at the time of death and
lesions found postmortem were also characteristic of EBOV dis-
ease in cynomolgus macaques (Table 1). Of the two SUDV survi-
vors that also survived EBOV challenge, one displayed mild clin-
ical signs of EBOV infection (fever and increased serum liver
enzymes), but with no detectable viremia (Table 1). The other
surviving NHP presented with mild fever on day 7 but otherwise
had no clinical signs of disease. Postmortem examination of the
two survivingNHPs revealed scattered hepaticmicroscopic foci of
very mild inflammation; however, there were no indications of an
ongoing viral infection at the time that these NHPs were eutha-
nized, as indicated by the lack of viremia. Moderate to marked
lymphoid hyperplasia was also present in their spleens and lymph
nodes.
Simultaneous vaccination with EBOV GP- and SUDV GP-
expressingVRP vaccines protects against EBOV and SUDV i.m.
challenge. Previous studies (41), in combination with the limited
protection of SUDV survivors against EBOV challenge observed
in the present studies, suggest that a bivalent ebolavirus vaccine
may be required to confer protection against both SUDV and
EBOV. To address this question we vaccinated six cynomolgus
macaques simultaneously with 1010 FFU of VRP-SUDV GP com-
bined with 1010 FFU of VRP-EBOV GP by i.m. injection. Control
NHPs received 1010 FFU of VRP expressing an irrelevant antigen
(influenza virus hemagglutinin), also by i.m. injection. As before,
serum was collected following vaccination to determine SUDV
and EBOV specific antibody titers. The dual VRP vaccination elic-
ited SUDV GP specific serum IgG titers of 5 to 6 logs at 14 days
postvaccination that then waned to 3.5 to 5 logs by day 28 post-
vaccination (Fig. 3A and B). EBOV GP specific serum IgG titers
were between 4 and 4.5 logs at day 14 postvaccination, and these
titers remained elevated or increased slightly to 4 to 5 logs by day
28 postvaccination (Fig. 3B and 4A). On day 28 postvaccination,
three vaccinatedNHPs and one control NHPwere challenged i.m.
with a target dose of 1,000 PFU of either SUDV or EBOV. The
control NHP challenged with SUDV succumbed on day 8 postin-
fection, and postmortem examination confirmed that it suc-
cumbed due to systemic SUDV infection. All vaccinated NHPs
were protected and showed no clinical signs of disease (Fig. 3C,
Table 2). Likewise, all vaccinated NHPs were protected against an
initial EBOV challenge, with no clinical signs of disease, whereas
the control NHP died on day 6 postinfection with classic clinical
signs and lesions of EBOV infection (Fig. 4C, Table 2). Having
survived exposure to either SUDV or EBOV, the six vaccinated
TABLE 1 VRP-SUDV GP-vaccinated macaques following i.m. filovirus challenge
Challenge type and NHPa Adverse events on days 1 to 28 after challengeb Status
After challenge with 1,000
PFU of SUDV i.m.
Ctrl 1 Fever (day 7), depression (day 7), mild rash (day 7), viremia (days 5 and 7), thrombocytopenia (day
7), 2- to 3-fold increase in ALT, AST, and ALP, 2- to 3-fold decrease in AMY
Succumbed on day 9
Ctrl 2 Fever (days 5 and 7), depression (day 6–8), widespread rash (days 7 and 8), anorexia (days 7 and 8),
viremia (days 5 and 7), thrombocytopenia (days 5 and 7),3-fold increase in ALT, AST, and
ALP
Succumbed on day 8
Exp 1 2- to 3-fold increase in AST and ALP (days 7 and 10) Survived
Exp 2 Fever (day 7), thrombocytopenia (day 5), 2- to 3-fold increase in ALP (days 7 and 10) Survived
Exp 3 Fever (day 7), depression (day 7), thrombocytopenia (day 5), 2- to 3-fold increase in AST and ALP
(days 7 and 10)
Survived
Exp 4 Anorexia (days 8 and 9), Survived
Exp 5 Anorexia (days 9 and 10), thrombocytopenia (day 5) Survived
Exp 6 Thrombocytopenia (day 5) Survived
After back-challenge with
1,000 PFU of EBOV i.m.
Ctrl 3 Fever (day 5), hypothermia (day 7), depression (days 6 and 7), mild rash (day 7), anorexia (days 6
and 7), viremia (days 5 and 7), thrombocytopenia (day 7), 2- to 3-fold increase in ALT,5-fold
increase in AST and ALP
Succumbed on day 7
Ctrl 4 Fever (days 5 and 7), depression (days 6 and 7), mild rash (days 6 and 7), anorexia (day 7), viremia
(days 5 and 7), thrombocytopenia (days 5 and 7),5-fold increase in ALT and AST, 4- to 5-fold
increase in ALP
Succumbed on day 8
Exp 1 Fever (day 5), hypothermia (day 7), depression (days 6 and 7), mild rash (day 7), anorexia (days 6
and 7), viremia (days 5 and 7), thrombocytopenia (day 7), 2- to 3-fold increase in ALT,5 fold
increase in ALP
Succumbed on day 7
Exp 2 Fever (days 5 and 7), depression (days 6 and 7), mild rash (days 6 and 7), anorexia (day 7), viremia
(day 7), thrombocytopenia (days 5 and 7),5-fold increase in ALT, AST, and ALP
Succumbed on day 8
Exp 3 Fever (days 5, 7, and 10), depression (days 6 to 10), 2- to 3-fold increase in ALT,5-fold increase
in ALP and AST
Survived
Exp 4 Fever (day 7) Survived
Exp 5 Fever (day 7), depression (day 18), anorexia (days 16 to 18) Succumbed on day 18
Exp 6 Fever (day 7), depression (day 14), mild rash (day 14), anorexia (day 14), thrombocytopenia (day
14),5-fold increase in ALT, AST, and ALP
Succumbed on day 14
a Ctrl, control animals; Exp, experimental animals.
b ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; AMY, amylase.
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NHPs and two new control NHPs were then challenged 28 or 30
days after the initial challenge with a target dose of 1,000 PFU of
the heterologous virus (SUDV survivors with EBOV on day 30
and EBOV survivors with SUDV on day 28). At the time of heter-
ologous challenge, EBOV GP and SUDV GP-specific serum IgG
titers remained elevated at 4.5 to 5.5 logs (Fig. 3B) and 5 to 5.5 logs
(Fig. 4B), respectively. After back-challenge, control NHPs suc-
cumbed to EBOV (Fig. 3D, Table 2) or SUDV (Fig. 4D, Table 2)
infection on days 8 and 7, respectively, and postmortem findings
confirmed that the NHPs died due to ebolavirus infection. Vacci-
natedNHPs survived back-challengewith EBOVanddisplayedno
clinical signs of EBOV infection (Fig. 3D, Table 2). Surprisingly,
only two of three vaccinated NHPs survived SUDV back-chal-
lenge, with these surviving NHPs having no clinical signs of dis-
ease (Fig. 4D, Table 2). The vaccinated NHP (experimental 10)
that did not survive this SUDV back-challenge experiment began
to display clinical signs typical of filovirus infection on day 7 post-
SUDV challenge and succumbed on day 10 (Fig. 4D, Table 2).
Postmortem examination revealed gross and histologic lesions
compatible with a systemic filovirus infection; however, immuno-
histochemistry (IHC) studies of the liver, spleen, and other se-
lected organs failed to detect the presence of ebolavirus antigens
(Fig. 5). Further investigation into the cause of death for this NHP
revealed that this animal died not from SUDV but from MARV,
likely through fomite or droplet transmission from MARV-in-
fectedNHPs housed in the same laboratory suite. At time of death,
FIG 3 Dual vaccination with VRP-SUDV GP and VRP-EBOV GP protects cynomolgus macaques from SUDV i.m. challenge. NHPs were vaccinated with VRP
expressing irrelevant antigen (n 1) orVRPs expressing both SUDVGPandEBOVGP (n 3). SUDVGP (A) or EBOVGP (B) specific serumantibody end titers
were determined by ELISA at the indicated times postvaccination or challenge. Dotted line indicates assay limit of detection. Black and red arrows indicate time
of SUDV challenge and EBOV back-challenge, respectively. (C) NHPs were challenged by i.m. injection of 1,000 PFU of SUDV 28 days postvaccination. (D)
SurvivingNHPswere then back challenged by i.m. injection of 1,000 PFU of EBOV 30 days post-SUDV challenge. **, P 0.01 (as determined by the Fisher exact
test).
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this NHPwas IHC and PCRnegative for SUDV and IHC and PCR
positive for MARV (Fig. 5, Fig. 6). All other NHPs were PCR
negative for MARV (data not shown).
Protection against aerosolized SUDV requires two vaccina-
tions with SUDV GP expressing VRP vaccine. To evaluate the
protective efficacy of the SUDV VRP vaccine against aerosol ex-
posure, cynomolgus macaques were vaccinated once (n  3) or
twice (n 3), 28 days apart, with 1010 FFU of VRP-SUDV GP by
i.m. injection. Control NHPs received either one dose (n 1) or
two doses (n  3) of 1010 FFU of VRP expressing an irrelevant
antigen (smallpox A33R) by i.m. injection. Serum was collected
following vaccination to assess SUDV GP-specific IgG titers.
NHPs that received a single vaccination had SUDV GP specific
serum IgG titers of 3.5 to 4.75 logs 14 days following vaccination
thatwaned to 2.75 to 3.75 logs by day 28 postvaccination (Fig. 7A).
For NHPs that received two vaccinations, SUDV GP specific se-
rum IgG titers increased from 3.5 to 4.5 logs at day 28 after pri-
mary vaccination to peak titers of 4.5 to 5.5 logs before diminish-
ing to 3.5 logs at the time of SUDV challenge (Fig. 7B). NHPswere
challenged 28 days following final vaccinationwith a target dose of
100 PFU of SUDV by the aerosol route. The four control animals
developed clinical signs typical of ebolavirus infection and all suc-
cumbed between days 7 and 9 (Fig. 7, Table 3). In contrast to
SUDV i.m. challenge, all three animals vaccinatedwith one dose of
VRP-SUDV GP presented with severe clinical signs and suc-
cumbed on day 7 or 8 following SUDV aerosol exposure (Fig. 7C,
Table 3). Postmortem examination revealed that these seven
monkeys had lesions in their livers and other organs typical of
those that occur with systemic SUDV infection after i.m. chal-
lenge. In addition, all of these animals had virus-induced lesions in
their respiratory tracts that appear to be unique to an aerosol route
of viral infection. Gross lung lesions included edema,multiple red
to tan foci of consolidation, and fibrinous pleuritis causing adhe-
sions between lung lobes and between the lobes and thoracic wall
(Fig. 8A). Histologically, there were multiple foci of acute fibrin-
ous to hemorrhagic pneumonia that often involved the overlying
pleura (Fig. 8C). The mediastinal lymph nodes, which receive
lymphatic drainage from the lungs, had acute necrotizing inflam-
mation and lymphoid depletion. IHC revealed abundant ebolavi-
rus antigen in the lung and lymph node lesions (Fig. 8D). All
NHPs that received two doses of VRP-SUDV GP survived SUDV
aerosol challenge with one asymptomatic animal, one displaying
TABLE 2 Pan-EBOV-vaccinated macaques following i.m. filovirus challenge
Challenge type and NHPa Adverse events on days 1 to 28 after challengeb Status
After challenge with 1,000
PFU of SUDV i.m.
Ctrl 5 Fever (days 5 and 7), depression (days 6 and 7), widespread rash (day 7), anorexia (days 5 to 7),
viremia (days 5 and 7), thrombocytopenia (days 5 and 7), 4- to 5-fold increase in ALT and
ALP,5-fold increase in AST
Succumbed on day 8
Exp 7 No clinical signs Survived
Exp 8 No clinical signs Survived
Exp 9 No clinical signs Survived
After back-challenge with
1,000 PFU of EBOV i.m.
Ctrl 6 Depression (days 6 and 7), anorexia (days 6 and 7), viremia (days 5 and 7), thrombocytopenia
(days 5 and 7), 4- to 5-fold increase in ALP,5-fold increase in ALT and AST
Succumbed on day 8
Exp 7 No clinical signs Survived
Exp 8 No clinical signs Survived
Exp 9 No clinical signs Survived
After challenge with 1,000
PFU of EBOV i.m.
Ctrl 7 Fever (day 5), hypothermia (day 6), widespread rash (day 6), anorexia (days 5 and 6), viremia
(days 3, 5, and 6), thrombocytopenia (days 5 and 6), 2- to 3-fold increase in ALP,5-fold
increase in ALT and AST
Succumbed on day 6
Exp 10 No clinical signs Survived
Exp 11 No clinical signs Survived
Exp 12 No clinical signs Survived
After back-challenge with
1,000 PFU of SUDV i.m.
Ctrl 8 Fever (days 5 and 7), depression (day 7), widespread rash (day 7), anorexia (days 6 and 7),
viremia (days 5 and 7), thrombocytopenia (days 5 and 7), 4- to 5-fold increase in ALT and
ALP,5-fold increase in AST
Succumbed on day 7
Exp 10 Fever (day 7), depression (days 7 to 9), mild rash (day 9), anorexia (days 8 and 9), viremia
(days 5 and 7),5-fold increase in ALT and AST
Succumbed on day 10c
Exp 11 No clinical signs Survived
Exp 12 No clinical signs Survived
a Ctrl, control animals; Exp, experimental animals.
b ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; AMY, amylase.
c Succumbed to MARV infection. PCR and antigen negative for SUDV at time of death.
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mild clinical signs (lymphopenia, fever,mild depression), and one
experiencing severe signs of ebolavirus infection (increased serum
liver enzymes, decreased platelets, lymphopenia, fever, depres-
sion, anorexia, weight loss) beforemaking a full recovery (Fig. 7D,
Table 3). Postmortem examination revealed multiple foci of
chronic granulomatous pneumonia in the twomacaques that had
displayed clinical signs, and ebolavirus antigen was detected by
IHC in some of these lesions but not in other areas of the lungs or
in any other tissues (Fig. 8E and F). The other asymptomatic an-
imal had only a few foci of mild chronic interstitial pneumonia
with no detectable viral antigens in any tissues. All three of these
survivors had moderate to marked lymphoid hyperplasia in their
spleens and lymph nodes.
DISCUSSION
The results presented here clearly demonstrate, for the first time,
the protective efficacy of ebolavirus VRP vaccines against SUDV
and EBOV challenge in cynomolgus macaques. Improved manu-
facturing processes (32–34) have allowed us to vaccinate with
higher doses (3 logs higher) of VRP vaccine compared to the
previously reported attempt, whichmay in part explain the differ-
ence in outcomes (31). It is possible that differences in the results
between the two studies may also be explained by differences in
the route of vaccine delivery, s.c. versus i.m. injections, although a
direct comparison of these two routes was not completed using
the same dose and VRP material. The SUDV GP and EBOV GP
FIG 4 Dual vaccination with VRP-SUDV GP and VRP-EBOV GP protects cynomolgus macaques from EBOV i.m. challenge. NHPs were vaccinated with VRP
expressing irrelevant antigen (n 1) orVRPs expressing both SUDVGPandEBOVGP (n 3). EBOVGP (A) or SUDVGP (B) specific serumantibody end titers
were determined by ELISA at the indicated times postvaccination or challenge. Dotted line indicates assay limit of detection. Black and red arrows indicate time
of EBOV challenge and SUDV back-challenge, respectively. (C) NHPs were challenged by i.m. injection of 1,000 PFU of EBOV 28 days postvaccination. (D)
SurvivingNHPswere then back challenged by i.m. injection of 1,000 PFU of SUDV 28 days post-EBOV challenge. **, P 0.01 (as determined by the Fisher exact
test).
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VRP vaccines proved to be quite potent since protection against
i.m. exposure to the corresponding ebolavirus was afforded fol-
lowing a single vaccination. TheVRP, VSV, and adenovirus-based
vaccines are the only filovirus vaccine candidates to provide full
protection to NHPs after only one vaccination (19, 41, 42). Po-
tency associated with the VRP-based vaccines may be partially
attributed to the propensity of VRPs to infect antigen-presenting
cells, in particular, dendritic cells (43). Natural adjuvant proper-
ties of VRPs are known to promote antigen-specific T cell immu-
nity and regulate a balanced antigen specific antibody response,
which may also contribute to the potency of the VRP vaccine
platform (44).
Differences in genomic nucleotide (37 to 41% homologous)
and amino acid (34 to 43% homologous) sequence homology
among ebolaviruses have made cross-species protection difficult.
This raises serious concerns about the efficacy of the current ebo-
lavirus vaccine platforms against emerging filoviruses (45). Jones
et al. previously reported that vaccination against EBOV and sub-
sequent survival of an EBOV infection in NHPs does not confer
complete protection against back-challenge with SUDV (41). We
report similar findings in that vaccination against SUDV and sub-
sequent survival of a SUDV infection in NHPs did not confer
protection against back-challenge with EBOV. These findings
lend further support towhat others before us have concluded: that
a pan-ebolavirus vaccine will likely require multiple components
specific for each ebolavirus. Here, we demonstrated the immuno-
genicity and protective efficacy of a dual-ebolavirus VRP vaccine
strategy that involves simultaneous vaccination with VRPs ex-
pressing SUDV and EBOV GPs. High antibody titers to both
SUDV GP and EBOV GP were generated following vaccination,
and all animals survived i.m. challenge with either virus. An effec-
tive multi-ebolavirus vaccination strategy has also been reported
for adenovirus and VSV-based filovirus vaccine candidates in
NHPs (18, 19). Collectively, these promising results suggest that
immune interference between multiple ebolavirus antigens is un-
likely to occur and does not adversely affect the downstream effi-
cacy of these vaccine platforms. This illustrates the feasibility of a
single, multifaceted ebolavirus vaccine that may protect against
multiple ebolaviruses. This does not eliminate the possibility that
a vaccine consisting of a single antigen will not be efficacious
FIG 5 Histologic lesions typical of filovirus infection in experimental animal 10. (A) Liver has diffuse vacuolar degeneration of hepatocytes adjacent to a central
vein (V), with foci of hepatocellular necrosis (arrowheads). (B) Spleen, with markedly decreased numbers of lymphocytes (i.e., lymphoid depletion) and
hemorrhage in a lymphoid nodule (N). Deposits of large amounts of fibrin in the surrounding red pulp appear as amorphous to fibrillar pink material. (C and
D) IHC of liver and spleen, respectively, fails to detect the presence of ebolavirus antigen. The greenish-brown granules present in some hepatocytes are bile
pigment. (E and F) IHC of liver and spleen, respectively, reveals abundant marburgvirus antigen (brown staining) within hepatic Kupffer cells, endothelial cells,
hepatocytes, and splenic histiocytes. Extracellular viral antigen is also present in areas of hepatic necrosis and in fibrin deposits in the spleen. Objective
magnification: 40 for liver photos and 10 for spleen photos.
FIG 6 Real-time PCR detection of filovirus. RNA was purified from whole
blood collected on day 7 postchallenge. One-step RT-PCRs were completed
using filovirus species-specific primers. Reciprocal critical threshold (CT)
values are reported. Dotted line indicates assay limit of detection (1
PFU/reaction).
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against diverse ebolaviruses or that heterologous cross-protection
is not feasible. Hensley et al. recently provided evidence that a
EBOV GP and SUDV GP specific DNA prime/adenovirus boost
vaccination strategy provided complete cross-protection against
BDBV exposure in NHPs (46). The authors stated that cross-re-
active T cell populations and not cross-reactive antibodies (unde-
tectable) may have contributed to this cross-protection. A more
recent report demonstrated that vaccination with an EBOV-spe-
cific VSV vaccine provided partial (75%) protection against
BDBV exposure in NHPs (47). Cross-reactive antibody titers to
BDBV GP were developed in two of four NHPs following vacci-
nation, although no correlation betweenBDBVGP antibody titers
and protection could be drawn. A cross-reactive T cell evaluation
was not reported. It is not clear whether the dual-ebolavirus VRP
vaccine presented here will provide cross-protection against other
ebolaviruses, known or yet to be discovered, nor is it understood
what effect the addition of MARV components may have on the
efficacy of a candidate pan-filovirus VRP vaccine. It is encourag-
ing to note, however, that a filovirus VSV vaccine platform, con-
sisting of EBOV, SUDV, and MARV specific components and
delivered simultaneously, protected NHPs from exposure to all
three viruses, as well as TAFV (18).
Protective efficacy against an aerosol exposure to filoviruses is
of paramount concern given that aerosol transmission represents
the most likely means of dispersing a biological weapon over a
populated area (14). Few filovirus vaccine candidates have been
tested against aerosolized filoviruses, and far less is known about
filovirus pathology and disease following aerosol exposure in
FIG 7 Vaccination with VRP-SUDVGP protects cynomolgusmacaques from SUDV aerosol challenge. NHPs were vaccinated with one (A andC) or two (B and
D) doses of VRP expressing irrelevant antigen or VRP expressing SUDV GP. SUDV GP specific serum antibody end titers were determined by ELISA at the
indicated times postvaccinationwith one (A) or two (B) doses of vaccine. Dotted line indicates assay limit of detection. (C)NHPs receiving one dose of irrelevant
VRP (n 1) or VRP-SUDV GP (n 3) were challenged by aerosol exposure to 100 PFU of SUDV 28 days postvaccination. (D) NHPs receiving two doses of
irrelevant VRP (n 3) or VRP-SUDV GP (n 3) were challenged by aerosol exposure to 100 PFU of SUDV 28 days following the second vaccination. **, P
0.01 (as determined by the Fisher exact test).
VRP Vaccine Protects NHPs from Ebolavirus Challenge
May 2013 Volume 87 Number 9 jvi.asm.org 4961
 
NHPs compared to i.m. challenge. The VSV vaccine platform was
the first to demonstrate protective efficacy in NHPs against aero-
solized MARV or EBOV (20). In these studies, NHPs were com-
pletely protected against aerosol exposure to MARV or EBOV
following a single vaccination with recombinant VSV expressing
MARV GP or EBOV GP, respectively. The authors noted that the
disease progression appeared to be slightly delayed compared to
i.m. challenge withMARV or EBOV. They also stated that despite
the route of infection, the lung seemed to be minimally involved
with regard to disease progression compared to other organs, such
TABLE 3 VRP-SUDV GP-vaccinated macaques after aerosol filovirus challenge
NHPa Adverse events on days 1 to 28 after challengeb Status
Ctrl 9 Depression (days 7 and 8), widespread rash (days 7 and 8), anorexia (days 7 and 8) viremia (days 3, 5, and 7),
thrombocytopenia (days 3, 5, and 7), 2- to 3-fold increase in ALT and ALP,5-fold increase in AST, 2- to 3-fold
decrease in AMY
Succumbed on day 9
Ctrl 10 Depression (days 6 to 8), widespread rash (days 6 and 7), anorexia (days 7 and 8), viremia (days 3, 5, and 7),
thrombocytopenia (days 5 and 7),5-fold increase in AST
Succumbed on day 9
Ctrl 11 Fever (day 7), depression (days 7 to 9), widespread rash (days 8 and 9), anorexia (days 8 and 9), bleeding from nose
(day 9), viremia (days 5 and 7), thrombocytopenia (days 5, 7, and 9), 2- to 3-fold increase in ALP,5-fold increase
in ALT and AST
Succumbed on day 9
Ctrl 12 Depression (days 6 and 7), widespread rash (day 7), anorexia (days 6 and 7), viremia (days 5 and 7), thrombocytopenia
(days 5 and 7),5-fold increase in ALT and ALP
Succumbed on day 7
Exp 13 Fever (day 5), depression (days 6 and 7), mild rash (day 7), anorexia (day 7), viremia (day 7), thrombocytopenia (days
3, 5, and 7), 2- to 3-fold increase in AST (day 7), 2- to 3-fold decrease in AMY
Succumbed on day 8
Exp 14 Depression (day 7), widespread rash (day 7), anorexia (day 7), viremia (day7), thrombocytopenia (day 7), 4- to 5-fold
increase in ALT,5-fold increase in AST and ALP, 2- to 3-fold decrease in AMY
Succumbed on day 8
Exp 15 Depression (day 6), mild rash (day 6), anorexia (day 6), thrombocytopenia (days 3 and 5), 2- to 3-fold decrease in AMY Succumbed on day 7
Exp 16 Fever (day 10), depression (days 9 to 12), anorexia (days 9 to 12) Survived
Exp 17 No clinical signs Survived
Exp 18 Depression (days 6 to 14), anorexia (days 6 to 14), viremia (day 5), 2- to 3-fold increase in ALP Survived
a Ctrl, control animals; Exp, experimental animals. All animals were challenged with 100 PFU of SUDV by aerosol.
b ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; AMY, amylase.
FIG 8 Pulmonary lesions associated with aerosolized SUDV. (A) Dorsal view of lungs and trachea (T) from experimental animal 13, after removal from the
thoracic cavity. There is diffuse pulmonary edema and a large area of dark-red consolidation (arrow) in the caudal aspect of the left superior lung lobe (S). The
pleural surface in this area and the leftmiddle lung lobe (M) is coveredwith tan-white fibrinous exudatewhich causes adhesions between the left superior,middle,
and inferior (I) lung lobes. (B) Histologic section of normal lung from a cynomolgus macaque that died after i.m. challenge with SUDV. Clear spaces are alveoli
and are separated by thin-walled septa and small blood vessels (V). (C) Histologic section of lung from control animal 12, which died 7 days after challenge with
aerosolized SUDV. The alveoli are filled by edema fluid, fibrin, and amixture of macrophages, neutrophils, and red blood cells. Alveolar septa are congested and
thickenedwith inflammatory cells. A small arteriole (A) is also present. (D) IHCof lung from control animal 12 reveals the presence of abundant intracellular and
extracellular ebolavirus antigen (brown staining). (E) Histologic section of a pulmonary granuloma in experimental animal 18, which survived a challenge with
aerosolized SUDV. The center of the granuloma (left 1/3 of the photo) contains suppurative inflammation, fibrin, and necrotic debris. The wall of the granuloma
(right 2/3 of the photo) is composed ofmacrophages, lymphocytes, plasma cells, and fibrous connective tissue. (F) IHCof a replicate section of the image in panel
E reveals ebolavirus antigen within macrophages and scattered extracellular antigen in the area of necrosis. Objective magnifications (B to F),20.
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as the liver and spleen. These findings are supported by recent
efforts of Pratt et al. in which the authors evaluated the efficacy of
an adenovirus 5 (Ad5) bivalent vaccine vector expressing EBOV
and SUDVGPs against aerosolized ebolaviruses in NHPs. As with
the previous report, this group demonstrated that a single vacci-
nation could protect against aerosolized EBOV and that lung le-
sions in the control animal were unremarkable compared to i.m.
challenge. This was not the case, however, for aerosol exposure to
SUDV. Control NHPs challenged with aerosolized SUDV devel-
oped significant lesions in their lungs and mediastinal lymph
nodes that were not seen in animals challenged by an i.m. route of
administration. Furthermore, a single vaccination with the biva-
lent Ad5 ebolavirus vaccine was unable to fully protect NHPs
against aerosol exposure to SUDV. Of more concern, the vacci-
nated NHP that succumbed to aerosolized SUDV infection pre-
sented with more severe lung lesions than those presented in the
control animals. These lesions were characterized by necrotizing
pneumonia and fibrinous pleuritis. The results of our studies sup-
port the findings reported by Pratt et al. in that aerosol exposure to
SUDV caused significant respiratory disease in control animals
and that a single vaccination with the VRP-SUDVGP vaccine was
unable to protect NHPs against aerosolized SUDV. Consistent
with the previous study, we also noted severe viral pneumonia and
fibrinous pleural adhesions in control and vaccinated NHPs that
succumbed to SUDV aerosol infection. As with the Ad5 vaccine, a
second booster vaccination with VRP-SUDVGP was able to elicit
protective immunity against aerosolized SUDV. However, with
both the Ad5 and the VRP vaccines, foci of chronic inflammation
were found in the respiratory tracts of twice-vaccinated animals
that had displayed clinical signs but survived challenge. Thus, un-
like EBOV orMARV aerosol exposure, NHPs exposed to aerosol-
ized SUDV seem to experience enhanced viral pathogenesis char-
acterized by complicating viral pneumonia in addition to classic
filovirus associated liver, spleen, and kidney failure. All indica-
tions thus far imply that protection against aerosolized SUDVmay
be more difficult to achieve compared to aerosolized EBOV or
MARV, suggesting that the SUDV aerosol model may represent
the most stringent standard for vaccine efficacy studies going for-
ward.
Although the results presented here are encouraging for the
overall development of an effective ebolavirus vaccine, it is
important to keep in mind that critical questions remain un-
answered. We have yet to evaluate the duration of protective
immunity associated with any of the ebolavirus VRP vaccines,
and little has been reported in the way of other ebolavirus
vaccine candidates regarding duration. Duration studies will
be critical in understanding the practical utility of various vac-
cine candidates, and these studies may provide critical infor-
mation needed to help select the best ebolavirus vaccine plat-
form to move forward to licensure. As with any vector-based
vaccine platform, preexisting immunity to the vector can have
deleterious effects on vaccine efficacy. The prevalence of im-
munity to VEEV is difficult to predict in populations of the
Americas where VEEV is endemic and results in sporadic hu-
man outbreaks (48, 49). The ebolavirus VRP vaccine candidate,
as well as any other vector-based vaccine, may be required to
demonstrate protective efficacy in the face of preexisting anti-
vector immunity in order to advance to licensure. Finally, the
mechanism by which the ebolavirus VRP vaccine induces pro-
tective immunity must be understood to gain U.S. Food and
Drug Administration licensure. The antibody titers reported
here clearly indicate that humoral immune responses are elic-
ited following VRP vaccination and provide a useful determi-
nant of seroconversion; however, these studies lack a compre-
hensive evaluation of both humoral and cellular immunity
needed to define correlates of immunity. As with other ebola-
virus vaccine candidates, clear correlates of immunity need to
be defined and appropriate parallels to human immune re-
sponses must be drawn. Ongoing efforts are aimed at address-
ing these unanswered questions as we move toward advanced
development and ultimately licensure of ebolavirus vaccines.
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